X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA FRESENIUS KABI ONCO. GSK PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 60.1 22.1 271.7% View Chart
P/BV x 11.8 3.1 378.8% View Chart
Dividend Yield % 2.1 0.0 -  

Financials

 GSK PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
GSK PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs3,850176 2,187.5%   
Low Rs2,96679 3,777.9%   
Sales per share (Unadj.) Rs332.337.7 881.8%  
Earnings per share (Unadj.) Rs44.35.1 869.7%  
Cash flow per share (Unadj.) Rs47.26.7 702.4%  
Dividends per share (Unadj.) Rs50.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs202.742.5 476.5%  
Shares outstanding (eoy) m84.70158.23 53.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.33.4 303.7%   
Avg P/E ratio x76.925.0 307.9%  
P/CF ratio (eoy) x72.218.9 381.3%  
Price / Book Value ratio x16.83.0 562.0%  
Dividend payout %112.90-   
Avg Mkt Cap Rs m288,64320,135 1,433.6%   
No. of employees `0004.61.2 400.3%   
Total wages/salary Rs m4,434703 630.5%   
Avg. sales/employee Rs Th6,104.55,176.2 117.9%   
Avg. wages/employee Rs Th961.6610.4 157.5%   
Avg. net profit/employee Rs Th813.7699.6 116.3%   
INCOME DATA
Net Sales Rs m28,1485,963 472.0%  
Other income Rs m1,21818 6,768.1%   
Total revenues Rs m29,3665,981 491.0%   
Gross profit Rs m4,7741,430 333.8%  
Depreciation Rs m248258 96.2%   
Interest Rs m0-26 0.0%   
Profit before tax Rs m5,7441,216 472.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m26-68 -38.2%   
Tax Rs m2,018342 589.7%   
Profit after tax Rs m3,752806 465.6%  
Gross profit margin %17.024.0 70.7%  
Effective tax rate %35.128.1 124.9%   
Net profit margin %13.313.5 98.6%  
BALANCE SHEET DATA
Current assets Rs m21,4625,102 420.7%   
Current liabilities Rs m10,5362,385 441.7%   
Net working cap to sales %38.845.6 85.2%  
Current ratio x2.02.1 95.2%  
Inventory Days Days68150 45.1%  
Debtors Days Days16113 14.5%  
Net fixed assets Rs m4,7175,148 91.6%   
Share capital Rs m847158 535.4%   
"Free" reserves Rs m16,3086,556 248.8%   
Net worth Rs m17,1716,732 255.1%   
Long term debt Rs m16952 1.7%   
Total assets Rs m30,62010,388 294.8%  
Interest coverage xNM-45.8-  
Debt to equity ratio x00.1 0.7%  
Sales to assets ratio x0.90.6 160.1%   
Return on assets %12.37.5 163.2%  
Return on equity %21.912.0 182.5%  
Return on capital %33.614.6 229.9%  
Exports to sales %074.5 0.0%   
Imports to sales %15.124.8 60.8%   
Exports (fob) Rs m44,441 0.1%   
Imports (cif) Rs m4,2371,477 286.8%   
Fx inflow Rs m5195,298 9.8%   
Fx outflow Rs m8,3201,772 469.5%   
Net fx Rs m-7,8013,525 -221.3%   
CASH FLOW
From Operations Rs m1,3861,274 108.8%  
From Investments Rs m5,010-1,204 -416.0%  
From Financial Activity Rs m-6,383-196 3,255.1%  
Net Cashflow Rs m12-126 -9.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 81.0 62.6%  
Indian inst/Mut Fund % 10.2 0.3 3,400.0%  
FIIs % 23.8 9.6 247.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   102,036 42,599 239.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  AJANTA PHARMA  UNICHEM LAB  

Compare GSK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS